Thank you for the opportunity to further elaborate.
MSF completely supports the capacity of pharmaceutical companies to make profits and to profit from bringing out new breakthroughs in pharmaceuticals. We have medical operations on hepatitis C, so we very much benefit from the new treatment and cures for hepatitis C.
What we think is unconscionable is to create a strategy for longer pharmaceutical monopolies beyond what currently exists under international law already. Just to give you the example of hepatitis C, for this new hepatitis C treatment, there are different prices around the world. In the United States right now, it's around $1,000 U.S. per pill. That's $84,000 per patient per treatment, while the same drug is available in generic competition and is available for less than $1 per pill.